Glycomine looks toward clinic with Novo-led $33M round

Glycomine raised a tranched $33 million series B round to take its lead rare congenital disease therapy into the clinic.

Novo Holdings A/S led the round. Additional new investors Asahi Kasei Pharma Corp. and Mission Bay Capital also participated, as did existing investors Sanderling and Chiesi Ventures...